Latest Breaking News On - Gilead sciences on - Page 3 : comparemela.com

(Reuters) -Gilead Sciences on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs. The drugmaker raised its full-year revenue forecast, even as it trimmed its estimate for COVID antiviral Veklury due to lower pandemic-related hospitalizations. Gilead reported second-quarter earnings of $1.34 per share excluding items, on total revenue of $6.6 billion, down from $1.58 a share and revenue of $6.26 billion in the year-ago quarter.

United statesDeena beasleyGilead sciences onWall streetReporting by deena beasleyMichael ermanBill berkrot